接种疫苗鸡的体内攻毒研究表明,基因型不匹配的疫苗仍对新城疫病毒提供显著保护
研究用拉索塔克隆30株、AV632-鸡-塞浦路斯-13(基因型VII.2)或模拟疫苗接种鸡两次后,以强毒AV632-鸡-塞浦路斯-13攻毒;两疫苗组临床保护水平相似,未接种组死亡率100%,接种组排毒显著减少,但异源疫苗组HN基因出现H199N和I192M突变。
要点
- 两疫苗组临床保护水平相似,未接种组死亡率为100%。
- 接种组排毒较未接种组显著减少,组织内病毒播散程度相当。
- 异源疫苗组HN基因出现H199N和I192M突变。
核心结论
- 现有疫苗配方对当代毒株提供相似水平的临床保护,循环毒株的抗原异质性不影响免疫鸡的排毒特征。
- 强毒APMV-1在免疫鸡群中致病不太可能仅由抗原不匹配导致,其他因素可能参与免疫失败和突破性感染。
研究设计与样本
- 体内疫苗-攻毒研究:鸡分组以灭活拉索塔克隆30株、AV632-鸡-塞浦路斯-13(基因型VII.2)或模拟疫苗两次接种(初免-加强),随后以强毒AV632-鸡-塞浦路斯-13攻毒。
主要发现
- 接种/攻毒两组临床保护水平相似,未接种组死亡率为100%。
- 接种组排毒较未接种组显著减少。
- 接种鸡组织内病毒播散程度相当,但感染起始延迟。
- 异源疫苗组HN基因观察到两个突变:H199N和I192M,后者被认为与融合潜力增加相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although commercial vaccines against Newcastle Disease have been available for decades, outbreaks still occur in the face of vaccination Further vaccination may accelerate viral evolution resulting in a further reduction in vaccine efficacy. A key question is whether genotype-matched vaccines can confer better protection against contemporary type 1 Avian Paramyxoviruses. To assess this, an in vivo vaccine-challenge study was undertaken to assess protection afforded by 'genotype-matched' and commercial vaccine formulations. Groups of chickens were vaccinated twice (prime-boost) with an inactivated preparation of either La Sota Clone 30, AV632-chicken-Cyprus-13 (genotype VII.2), or mock vaccine, and later challenged with virulent AV632-chicken-Cyprus-13. Post vaccinal serological responses differed, although both vaccination/challenge groups showed similar levels of clinical protection compared to the unvaccinated group, where 100 % mortality was observed. Shedding was significantly reduced in the vaccinated groups compared to the unvaccinated group. Virus dissemination in the tissues of vaccinated birds was comparable, but onset of infection was delayed. Two mutations were observed in the HN gene of the heterologous vaccine group; H199N and I192M, the latter thought to be associated with increased fusogenic potential. These data demonstrate that existing vaccine formulations confer similar levels of clinical protection to contemporary strains and that the antigenic heterogeneity of circulating strains does not impact upon shedding profiles in immunised birds. In conclusion, the ability of virulent APMV-1 to cause disease in vaccinated flocks is unlikely to be the result of antigenic mismatch alone, and other factors likely contribute to vaccination failure and breakthrough.
引用
- Mahmood S, Skinner P, Warren CJ, et al. In vivo challenge studies on vaccinated chickens indicate a virus genotype mismatched vaccine still offers significant protection against NDV. Vaccine. 2023. PMID: 38143198. doi:10.1016/j.vaccine.2023.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。